Contact Us
Drug Search Results
More Filters [+]

Velmanase alfa

Alternative Names: velmanase alfa
Latest Update: 2024-09-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Enzyme Replacement Therapy

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Velmanase alfa

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: alpha-Mannosidosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2013-000336-97

P3

Completed

alpha-Mannosidosis

2022-09-30

Phase IIIb

P3

Completed

alpha-Mannosidosis

2022-09-30

Recent News Events

Date

Type

Title

02/08/2024

News Article

 Chiesi Global Rare Diseases Presents Long-Term Data on Treatment with Velmanase Alfa in Alpha-Mannosidosis and Announces Additional Presentations at the 20th Annual WORLDSymposium™ Research Meeting

09/01/2023

News Article

 Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023

02/24/2023

News Article

 Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting

02/16/2023

News Article

 Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions